Protocol Ledger

NCT05071300 · Phase III · ACTIVE NOT RECRUITING

A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Interventional Phase III clinical trial protocol NCT05071300 sponsored by Ionis Pharmaceuticals in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-01-04 Enrollment: 151 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05071300
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)151 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05071300
Protocol FieldVerified Registry Value
NCT IdentifierNCT05071300
Consolidated Lead SponsorIonis Pharmaceuticals
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment151 participants (ACTUAL)
Registered Start Date2022-01-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI